Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AZD1775 as monotherapy or in combination with chemothera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Leijen, Suzanne, van Geel, Robin M.J.M., Pavlick, Anna C., Tibes, Raoul, Rosen, Lee, Razak, Albiruni R. Abdul, Lam, Raymond, Demuth, Tim, Rose, Shelonitda, Lee, Mark A., Freshwater, Tomoko, Shumway, Stuart, Liang, Li Wen, Oza, Amit M., Schellens, Jan H.M., Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7845944/
https://ncbi.nlm.nih.gov/pubmed/27601554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.5991
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados